NOVOsyn® for Trocar Incision After Laparoscopic Appendectomy and Cholecystectomy

Appendicitis Clinical Trial

— NOVOTILAC  

Official title:

Randomized, Multi-center, Double Blinded, Prospective Study to Evaluate the Incidence of Complications in Laparoscopic Cholecystectomy and Appendectomy Using Novosyn® CHD Versus Novosyn® Suture Material to Close Trocar Wound

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04033211
• Other study ID #: AAG-O-H-1816
• Status: Completed
• Start date: February 13, 2020
• Est. completion date: September 11, 2023

Study information

• Verified date: September 2023
• Source: Aesculap AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate if the application of a Chlorhexidine coated suture (Novosyn® CHD) will reduce the colonization of bacteria in comparison to an uncoated suture (Novosyn®) used for the closure of trocar wounds in laparoscopic surgery (appendectomy and cholecystectomy).

Description:

The bacteriostatic and bactericidal effect of Novosyn® CHD will be assessed by the incidence of surgical site infection (SSI) in each suture group until 30 days postoperatively. The frequency of infections (SSI: A1 and A2) is considered as a suitable parameter for the assessment of efficacy. It is expected that the use of the Novosyn® CHD suture will reduce the occurrence of infections (SSI: A1 and A2) 30 days postoperatively compared to Novosyn suture (primary objective). SSI will be classified according to the Centre of Disease Control and Prevention (CDC), therefore the time point for assessment of SSI as set to 30 days postoperatively. Furthermore, short-term and long-term complications, the handling of the suture material, length of postoperative hospital stay, costs, pain, quality of life, time to return to work, hernia rate including umbilical hernias and the cosmetic outcome will also be assessed as secondary objectives.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 316
• Est. completion date: September 11, 2023
• Est. primary completion date: August 24, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or cholecystectomy.
• Written informed consent
• Age= 18 years
• Not incapacitated patient

Exclusion Criteria:

• Open surgery for appendectomy or cholecystectomy
• Pregnancy
• Allergy or hypersensitivity to chlorhexidine
• Intraoperatively conversion from laparoscopic to open surgery
• Patients taking medical consumption that might affect wound healing

Related Conditions & MeSH terms

• Appendicitis
• Cholecystitis

Intervention

Device:
• Novosyn® CHD for fascia and skin closure
Experimental
• Novosyn® for fascia and skin closure
Comparator

Locations

Country	Name	City	State
Germany	Klinikverbund Südwest Krankenhaus Leonberg Alllgemeinchirurgie	Leonberg	Baden-Württemberg
Germany	Diakonie Klinikum gGmbH Schwäbisch Hall	Schwäbisch Hall	Baden-Württemberg
Spain	Hospital Germans Trias i Pujol General and Digestive Surgery	Badalona
Spain	General Surgery Department Hospital Plató	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Aesculap AG	B.Braun Surgical SA

Countries where clinical trial is conducted

Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgical Site Infection	Incidence of postoperative surgical site infections, SSI (A1: Superficial incisional site infections and A2: Deep incisional surgical site infections) (efficacy parameter) Surgical Site Infection (SSI) is defined according to the definition of the US Centres for Disease Control and Prevention (CDC).	until 30 days + 10 days after surgery
Secondary	Development of Wound Dehiscence	Incidence of wound dehiscence (skin) at different postoperative examinations	until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
Secondary	Reoperation Rate	Incidence of reoperation rate at different postoperative times	until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
Secondary	Mortality Rate	Incidence of mortality rate at different postoperative times	until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively
Secondary	Postoperative Complications during the postoperative Course	Rates of postoperative complications such as bleeding, tissue reaction, abscess, perforation, bile leaks, biliary peritonitis, ileus, stenosis, fistula at different postoperative points in time	until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively
Secondary	Suture Removal due to Wound Problems during the postoperative Course	Rate of suture removal due to wound problems (infection, dehiscence, residual material requiring removal) at different defined postoperative points in time	until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively
Secondary	Length of hospital stay	Defined as the time period from day of operation until day of discharge (efficacy parameter).	until discharge (ca. 10 days postop)
Secondary	Postoperative Surgical Site Infections	Incidence of postoperative surgical site infections	1 year ±2 months post-op
Secondary	Rate of Conversion to open surgery	Number of interventions where operation technique has to be converted to open surgery intraoperatively	intraoperatively
Secondary	Time to return to work	Defined as the duration (days) from day of surgery until the day when the patient was able to work. Employment status of the patient will also be reported.	up to 1 year ±2 months
Secondary	Course of Pain: Visual Analogue Scale (VAS)	This parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "maximal pain". The values are compared over postoperative period.	preoperatively, at day of discharge (ca. 10 days postop), at 30 days +10 days and 1 year ±2 months postoperatively
Secondary	Course of Cosmetic result	Overall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS). Cosmetic result and the scar will be evaluated by the patient and the physician. Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each. The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each. The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum)	30 days +10 days, 1 year ±2 months postoperatively
Secondary	Course of Overall patient and observer satisfaction with the scar: Patient and Observer Scar Assessment Scale (POSAS)	Overall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS). Cosmetic result and the scar will be evaluated by the patient and the physician. Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each. The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each. The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum)	30 days +10 day, 1 year ±2 months postoperatively
Secondary	Comparison of wound appearance	Photographic documentation of the wounds for assessment	discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
Secondary	Comparison of handling parameters of the suture materials	Comparison of the handling features of the suture materials in eight different categories (ease of passage of the suture, first throw knot holding, knot tie down smoothness, knot security, surgical hand, memory effect, lack of frying and the overall handling) by rating each category on a 5 point scale (excellent, very good, good, satisfied, poor); no overall score is calculated, the categories are compared separately	intraoperatively
Secondary	Course of Health Status	EQ-5D is a standardised measure of health status developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D is designed for self-completion by respondents and it takes only a few minutes to complete. Instructions to respondents are included in the questionnaire. EQ-5D-5L consists of 2 pages - descriptive system and the EQ visual Analogue scale (EQ-VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the respondents self rated health on a 20 cm vertical , visual analogue scale with endpoints labelled "the best health you can imagine" and " the worst health you can imagine"	30 days +10 days after surgery, 1 year ±2 months after surgery
Secondary	Hernia Rate / Umbilical Hernia Rate	Hernia rate including umbilical hernia postoperatively verified by ultra-sound examination compared at different postoperative points in time	until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively
Secondary	Costs (economics)	Assessment of costs will be calculated on postoperative complication (SSI) in both suture groups (efficient parameter).	1 year ±2 months